|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2004-9-9
|
|
pubmed:abstractText |
Oral erythromycin prolongs cardiac repolarization and is associated with case reports of torsades de pointes. Because erythromycin is extensively metabolized by cytochrome P-450 3A (CYP3A) isozymes, commonly used medications that inhibit the effects of CYP3A may increase plasma erythromycin concentrations, thereby increasing the risk of ventricular arrhythmias and sudden death. We studied the association between the use of erythromycin and the risk of sudden death from cardiac causes and whether this risk was increased with the concurrent use of strong inhibitors of CYP3A.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amoxicillin,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Aryl Hydrocarbon Hydroxylases,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP3A,
http://linkedlifedata.com/resource/pubmed/chemical/Diltiazem,
http://linkedlifedata.com/resource/pubmed/chemical/Erythromycin,
http://linkedlifedata.com/resource/pubmed/chemical/Nitroimidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Oxidoreductases, N-Demethylating,
http://linkedlifedata.com/resource/pubmed/chemical/Troleandomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Verapamil
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2004 Massachusetts Medical Society
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
9
|
|
pubmed:volume |
351
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1089-96
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:15356306-Administration, Oral,
pubmed-meshheading:15356306-Adult,
pubmed-meshheading:15356306-Aged,
pubmed-meshheading:15356306-Amoxicillin,
pubmed-meshheading:15356306-Anti-Bacterial Agents,
pubmed-meshheading:15356306-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:15356306-Calcium Channel Blockers,
pubmed-meshheading:15356306-Confounding Factors (Epidemiology),
pubmed-meshheading:15356306-Cytochrome P-450 CYP3A,
pubmed-meshheading:15356306-Death, Sudden, Cardiac,
pubmed-meshheading:15356306-Diltiazem,
pubmed-meshheading:15356306-Drug Interactions,
pubmed-meshheading:15356306-Erythromycin,
pubmed-meshheading:15356306-Female,
pubmed-meshheading:15356306-Humans,
pubmed-meshheading:15356306-Male,
pubmed-meshheading:15356306-Middle Aged,
pubmed-meshheading:15356306-Multivariate Analysis,
pubmed-meshheading:15356306-Nitroimidazoles,
pubmed-meshheading:15356306-Oxidoreductases, N-Demethylating,
pubmed-meshheading:15356306-Risk,
pubmed-meshheading:15356306-Troleandomycin,
pubmed-meshheading:15356306-Verapamil
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Oral erythromycin and the risk of sudden death from cardiac causes.
|
|
pubmed:affiliation |
Division of Pharmacoepidemiology, Department of Preventive Medicine Vanderbilt University School of Medicine, Nashville, USA. cindy.naron@vanderbilt.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
